Trying to get out of IBM

[Anonymous]

Novartis is always trying to get away from IBM. That will never happen.
But it will come at cost an enorimous amount of cost and pain for Novartis without a reason.

The process is 5 years started and has not progressed since James took it over as he has no clue and what to do with operations. He is all about projects and even there...highly questionnable. Norton may have had a chance in doing the unwinding but got stabbed in the back by all his Novartis friends.

 

[Anonymous]

5 years? Novartis has had a love hate relationship with IBM for over a decade.

 

[Anonymous]

"Norton...all his Novartis friends."

huge assumption

 

[Anonymous]

"Novartis is always trying to get away from IBM. That will never happen.
But it will come at cost an enorimous amount of cost and pain for Novartis without a reason."

never say never. ;-)

how enormous the cost and the pain?

but, you said....huh?

sense, have you?

 

[Anonymous]

I heard from an AstraZeneca colleague that they tossed IBM out and gave the work IBM had to some combination of Cognizant, Accenture, HCL and wipro.

Also heard recently that Pfizer might have tossed IBM - though that was not confirmed.

So other pharmaceutical companies are tossing them. Why not us??

 

[Anonymous]

"they tossed IBM out and gave the work IBM had to some combination of Cognizant, Accenture, HCL and wipro."

how is that working out?

 

[Anonymous]

if not ibm, then who?

 

[Anonymous]

dead thread?

 

[Anonymous]

dead thread?

no. just a bunch of watchers. ;-)

 

[Anonymous]

"they tossed IBM out and gave the work IBM had to some combination of Cognizant, Accenture, HCL and wipro."

how is that working out?

I hear that it has worked out so well that their new CIO has decided to move toward insourcing many of the IT functions away from this new "ecosystem" of suppliers, fire most of the current local IT employees and replace them with some cheap captive offshore employees (i.e., same bunch of incompetent Indians, just wearing an AZ badge). Yeah, that'll fix it.

Be careful what you wish for.

 

[Anonymous]

I hear that it has worked out so well that their new CIO has decided to move toward insourcing many of the IT functions away from this new "ecosystem" of suppliers, fire most of the current local IT employees and replace them with some cheap captive offshore employees (i.e., same bunch of incompetent Indians, just wearing an AZ badge). Yeah, that'll fix it.

Be careful what you wish for.

https://www.youtube.com/watch?v=EFGa9QIrrC4

 

[Anonymous]

http://www.bloomberg.com/news/2013-12-12/ibm-sued-over-claim-spy-program-cooperation-hurt-sales.html
An International Business Machines Corp. (IBM) shareholder sued claiming the company’s cooperation with a National Security Agency eavesdropping program hurt investors as China sales dropped.

The Louisiana Sheriffs’ Pension and Relief Fund, in a complaint filed yesterday in Manhattan federal court, accuses IBM of defrauding investors by concealing the sales decline after Edward Snowden leaked information that the company was cooperating with the NSA.

IBM lobbied in favor of a bill that would allow it to share customers’ personal data, including data from customers in China, with the NSA, according to the complaint. In June, documents released by Snowden disclosed the NSA’s “Prism” surveillance program, which used information from technology companies such as IBM, the pension fund said.

 

[Anonymous]

http://www.fiercebiotechit.com/stor.../2014-09-20?utm_medium=nl&utm_source=internal

AstraZeneca ($AZN) is following the well-trodden path of offshoring part of its IT to India. But unlike some of its peers--and in a reversal of its own strategy--the Big Pharma is adding in-house capacity and lessening its reliance on IT service providers.

The opening of a $9 million IT facility in Chennai, India, has given AstraZeneca the capacity to pull work back from vendors. AstraZeneca currently employs 75 people at the site, but is in the middle of a hiring spree that will grow headcount to 300 by the end of the year. The facility is the first component of a three-step strategy to add IT capacity. AstraZeneca plans to open a second site in San Francisco in 2015, with a third to follow in Eastern Europe within the next two years.

Once all three sites are operational, AstraZeneca will have the capacity to handle the majority of its IT needs. "There is a shift in the strategy with most of the outsourcing works will become in-house operations. At present 70% of the IT spend is with third parties and this would become 30% in next three years," AstraZeneca Chief Information Officer David Smoley told Business Standard. By bringing work in house, Smoley hopes to lower AstraZeneca's IT spending from last year's outlay of $1.3 billion.

The change marks the beginning of the end of AstraZeneca's 13-year experiment with IT outsourcing. AstraZeneca got deep into IT outsourcing in 2001 when it struck a 7-year, $1.7 billion deal with IBM ($IBM). At the time, AstraZeneca doubted whether it would ever resume in-house management of its IT infrastructure. The IBM deal was extended in 2007 but ended in 2011. With the drug industry changing quickly, AstraZeneca felt it was better served by using a pool of IT service suppliers.

AstraZeneca struck deals with HCL Technologies and other suppliers, but now seems to have decided this model is flawed, too. The expectation is that bringing work in house will lower costs, increase efficiencies and make data safer.

 

[Anonymous]

http://www.fiercebiotechit.com/stor.../2014-09-20?utm_medium=nl&utm_source=internal

AstraZeneca ($AZN) is following the well-trodden path of offshoring part of its IT to India. But unlike some of its peers--and in a reversal of its own strategy--the Big Pharma is adding in-house capacity and lessening its reliance on IT service providers.

The opening of a $9 million IT facility in Chennai, India, has given AstraZeneca the capacity to pull work back from vendors. AstraZeneca currently employs 75 people at the site, but is in the middle of a hiring spree that will grow headcount to 300 by the end of the year. The facility is the first component of a three-step strategy to add IT capacity. AstraZeneca plans to open a second site in San Francisco in 2015, with a third to follow in Eastern Europe within the next two years.

Once all three sites are operational, AstraZeneca will have the capacity to handle the majority of its IT needs. "There is a shift in the strategy with most of the outsourcing works will become in-house operations. At present 70% of the IT spend is with third parties and this would become 30% in next three years," AstraZeneca Chief Information Officer David Smoley told Business Standard. By bringing work in house, Smoley hopes to lower AstraZeneca's IT spending from last year's outlay of $1.3 billion.

The change marks the beginning of the end of AstraZeneca's 13-year experiment with IT outsourcing. AstraZeneca got deep into IT outsourcing in 2001 when it struck a 7-year, $1.7 billion deal with IBM ($IBM). At the time, AstraZeneca doubted whether it would ever resume in-house management of its IT infrastructure. The IBM deal was extended in 2007 but ended in 2011. With the drug industry changing quickly, AstraZeneca felt it was better served by using a pool of IT service suppliers.

AstraZeneca struck deals with HCL Technologies and other suppliers, but now seems to have decided this model is flawed, too. The expectation is that bringing work in house will lower costs, increase efficiencies and make data safer.

old, overpaid westerners remotely managing a modern-day slavery hub in India.
deja vu all over again.

 

[Anonymous]

http://www.fiercebiotechit.com/stor.../2014-09-20?utm_medium=nl&utm_source=internal

AstraZeneca ($AZN) is following the well-trodden path of offshoring part of its IT to India. But unlike some of its peers--and in a reversal of its own strategy--the Big Pharma is adding in-house capacity and lessening its reliance on IT service providers.

The opening of a $9 million IT facility in Chennai, India, has given AstraZeneca the capacity to pull work back from vendors. AstraZeneca currently employs 75 people at the site, but is in the middle of a hiring spree that will grow headcount to 300 by the end of the year. The facility is the first component of a three-step strategy to add IT capacity. AstraZeneca plans to open a second site in San Francisco in 2015, with a third to follow in Eastern Europe within the next two years.

...

And now India is over here asking the US for money and other resources to upgrade its various infrastructure needs. I don't think so. If you can't deliver the basic infrastructure requirements for data centers, then you lose!